Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Jonsson Comprehensive Cancer Center
OBJECTIVES:
* Determine the biodistribution of fluorine F 18 FEQA in patients with stage III or IV non-small cell lung cancer (NSCLC) and in healthy participants.
* Determine whether fluorine F 18 FEQA can be used as an imaging agent with positron emission tomography in patients with stage III or IV NSCLC.
OUTLINE: This is a pilot study.
Patients and healthy participants receive fluorine F 18 FEQA IV and then undergo whole-body dynamic scans comprising positron emission tomography.
Blood is collected during and after imaging to measure radioactivity.
PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Must meet 1 of the following criteria:
Diagnosis of non-small cell lung cancer by CT scan, bone scan, or biopsy
* Stage III or IV disease
* Clinically assessed with
Healthy participant
Clareo Health | Fluorine F 18 FEQA in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer and in Healthy Participants
